Equity Overview
Price & Market Data
Price: $23.05
Daily Change: -$1.35 / 5.86%
Daily Range: $22.67 - $24.63
Market Cap: $1,459,493,760
Daily Volume: 1,630,086
Performance Metrics
1 Week: 4.74%
1 Month: 7.77%
3 Months: -21.14%
6 Months: 51.36%
1 Year: 80.79%
YTD: -2.09%
Company Details
Employees: 209
Sector: Health technology
Industry: Biotechnology
Country:
Details
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.